Ataxia Telangiectasia Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Erydel, IntraBio Inc., Matrix Biomed, Inc
The Ataxia Telangiectasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ataxia Telangiectasia pipeline products will significantly revolutionize the Ataxia Telangiectasia market dynamics.
Ataxia Telangiectasia Overview
Ataxia telangiectasia (AT) is a complex genetic neurodegenerative disorder that may become apparent during infancy or early childhood. The disorder is characterized by progressively impaired coordination of voluntary movements (ataxia), the development of reddish lesions of the skin and mucous membranes due to permanent widening of groups of blood vessels (telangiectasia), and impaired functioning of the immune system (i.e., cellular and humoral immunodeficiency), resulting in increased susceptibility to upper and lower respiratory infections (sinopulmonary infections).
Some of the key facts of the Ataxia Telangiectasia Market Report:
- The Ataxia Telangiectasia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to the National Cancer Institute, the risk of an Ataxia-Telangiectasia patient developing any cancer is 37-fold higher than individuals in the general population
- As per the National Library of Medicine, Ataxia-Telangiectasia occurs in 1 in 40,000–100,000 people worldwide
- As per the studies of Giulietta et al., the United States, about 1% of the population is a carrier of a mutation in the Ataxia-Telangiectasia mutated kinase (ATM) gene
- Key Ataxia Telangiectasia Companies: Erydel, IntraBio Inc., Matrix Biomed, Inc, and others
- Key Ataxia Telangiectasia Therapies: EryDex, IB1001, MBM-01, and others
- The Ataxia Telangiectasia epidemiology based on gender analyzed that males and females are affected in equal numbers by Ataxia Telangiectasia
Get a Free sample for the Ataxia Telangiectasia Market Report
Key benefits of the Ataxia Telangiectasia Market report:
- Ataxia Telangiectasia market report covers a descriptive overview and comprehensive insight of the Ataxia Telangiectasia Epidemiology and Ataxia Telangiectasia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Ataxia Telangiectasia market report provides insights on the current and emerging therapies.
- Ataxia Telangiectasia market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Ataxia Telangiectasia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Ataxia Telangiectasia market.
Discover more about therapies set to grab major Ataxia Telangiectasia market share @ Ataxia Telangiectasia market forecast
Ataxia Telangiectasia Epidemiology Segmentation:
The Ataxia Telangiectasia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Ataxia Telangiectasia
- Prevalent Cases of Ataxia Telangiectasia by severity
- Gender-specific Prevalence of Ataxia Telangiectasia
- Diagnosed Cases of Episodic and Chronic Ataxia Telangiectasia
Ataxia Telangiectasia Market
The dynamics of the Ataxia Telangiectasia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as EryDex , IB1001, MBM-01, and others during the forecasted period 2019-2032.
Download the report to understand which factors are driving Ataxia Telangiectasia epidemiology trends @ Ataxia Telangiectasia Epidemiological Insights
Ataxia Telangiectasia Therapies and Key Companies
- EryDex: Erydel
- IB1001: IntraBio Inc.
- MBM-01: Matrix Biomed, Inc
Scope of the Ataxia Telangiectasia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Ataxia Telangiectasia Companies: Erydel, IntraBio Inc., Matrix Biomed, Inc, and others
- Key Ataxia Telangiectasia Therapies: EryDex, IB1001, MBM-01, and others
- Ataxia Telangiectasia Therapeutic Assessment: Ataxia Telangiectasia current marketed and Ataxia Telangiectasia emerging therapies
- Ataxia Telangiectasia Market Dynamics: Ataxia Telangiectasia market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Ataxia Telangiectasia Market Access and Reimbursement
Table of Contents
1. Ataxia Telangiectasia Market Report Introduction
2. Executive Summary for Ataxia Telangiectasia
3. SWOT analysis of Ataxia Telangiectasia
4. Ataxia Telangiectasia Patient Share (%) Overview at a Glance
5. Ataxia Telangiectasia Market Overview at a Glance
6. Ataxia Telangiectasia Disease Background and Overview
7. Ataxia Telangiectasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Ataxia Telangiectasia
9. Ataxia Telangiectasia Current Treatment and Medical Practices
10. Ataxia Telangiectasia Unmet Needs
11. Ataxia Telangiectasia Emerging Therapies
12. Ataxia Telangiectasia Market Outlook
13. Country-Wise Ataxia Telangiectasia Market Analysis (2019–2032)
14. Ataxia Telangiectasia Market Access and Reimbursement of Therapies
15. Ataxia Telangiectasia Market drivers
16. Ataxia Telangiectasia Market barriers
17. Ataxia Telangiectasia Appendix
18. Ataxia Telangiectasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Ataxia Telangiectasia treatment, visit @ Ataxia Telangiectasia Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/